SONN

Sonnet BioTherapeutics Holdings, Inc.

2.00 USD
+0.19 (+10.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Sonnet BioTherapeutics Holdings, Inc. stock is up 36.05% since 30 days ago. The next earnings date is May 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.11% of the previous 18 March’s closed higher than February. 100% of analysts rate it a buy.

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc. develops platform for biologic medicines of single or bispecific action. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.